Anixa Biosciences Announces Positive Early Trial Results for Cancer Treatments

Anixa Biosciences has reported encouraging data from its Phase 1 clinical trial for a breast cancer vaccine, meeting primary endpoints and showing strong immune responses. Additionally, the company observed positive survival trends in an ongoing Phase 1 trial for an ovarian cancer CAR-T therapy. These early findings suggest potential advancements in cancer treatment. The results were presented at a recent cancer immunotherapy symposium.